Abstract:Apolipoprotein E4 (APOE4), although yet-to-be fully understood, increases the risk and lowers the age of onset of Alzheimer's disease (AD), which is the major cause of dementia among elderly individuals. The endosome-lysosome and autophagy pathways, which are necessary for homeostasis in both neurons and glia, are dysregulated even in early AD. Nonetheless, the contributory roles of these pathways to developing AD-related pathologies in APOE4 individuals and models are unclear. Therefore, this review summarizes the dysregulations in the endosome-lysosome and autophagy pathways in APOE4 individuals and non-human models, and how these anomalies contribute to developing AD-relevant pathologies. The available literature suggests that APOE4 causes endosomal enlargement, increases endosomal acidification, impairs endosomal recycling, and downregulates exosome production. APOE4 impairs autophagy initiation and inhibits basal autophagy and autophagy flux. APOE4 promotes lysosome formation and trafficking and causes ApoE to accumulate in lysosomes. APOE4-mediated changes in the endosome, autophagosome and lysosome could promote AD-related features including Aβ accumulation, tau hyperphosphorylation, glial dysfunction, lipid dyshomeostasis, and synaptic defects. ApoE4 protein could mediate APOE4-mediated endosome-lysosome-autophagy changes. ApoE4 impairs vesicle recycling and endosome trafficking, impairs the synthesis of autophagy genes, resists being dissociated from its receptors and degradation, and forms a stable folding intermediate that could disrupt lysosome structure. Drugs such as molecular correctors that target ApoE4 molecular structure and enhance autophagy may ameliorate the endosome-lysosome-autophagy-mediated increase in AD risk in APOE4 individuals.

ApoE4 activates C/EBPβ/δ-secretase with 27-hydroxycholesterol, driving the pathogenesis of Alzheimer’s disease

Neuronal ApoE4 stimulates C/EBPβ activation, promoting Alzheimer’s disease pathology in a mouse model

C/EBPβ/AEP Signaling Activated by ApoE4 and 27-Hydroxycholesterol in Macrophages Mediates Cerebral Amyloid Angiopathies in Alzheimer’s Disease

C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer’s disease

ApoE 4 Reduces the Expression of Aβ Degrading Enzyme IDE by Activating the NMDA Receptor in Hippocampal Neurons

C/EBPβ/AEP signaling couples atherosclerosis to the pathogenesis of Alzheimer’s disease

Cholesterol and Matrisome Pathways Dysregulated in Human APOE Ε4 Glia

Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches

AÃÂ² Metabolism and the Role of APOE in AlzheimerÃ¢ÂÂs Disease

ApoE4 Accelerates Early Seeding of Amyloid Pathology

Aβ Metabolism and the Role of APOE in Alzheimer’s Disease

Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer’s disease pathogenesis

Neuronal ApoE4 in Alzheimer's disease and potential therapeutic targets

Cholesterol and matrisome pathways dysregulated in astrocytes and microglia

Peripheral Apoe4 Enhances Alzheimer’s Pathology and Impairs Cognition by Compromising Cerebrovascular Function

FSH and ApoE4 Contribute to Alzheimer’s Disease-Like Pathogenesis Via C/EBPβ/δ-secretase in Female Mice

The Contributions of the Endolysosomal Compartment and Autophagy to APOE ɛ4 Allele-Mediated Increase in Alzheimer's Disease Risk

APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes

APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β

Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease

The Contributions of the Endolysosomal Compartment and Autophagy to APOEɛ4 Allele-Mediated Increase in Alzheimer's Disease Risk